You would expect a cannabis consumer to be highly diabetic, right? What with the sweet tooth, munchies and seemingly lazy lifestyle, cannabis smokers should all be having diabetes levels that are way off the charts. But surprise, surprise...Most cannabis smokers seem to have normal, or even lower, diabetes than average, in spite of all the above stereotyped lifestyle indicators.
The Indian Hemp Drugs Commission of 1894-95 says in the medical uses of cannabis in 19th century India, under the section Treatment of disease, that 'In diseases of the urinary organs hemp preparations are used in diabetes...' Rev. J. Desigachari, Missionary, Society for the Propagation of the Gospel, Badvel, Cuddapah District, says, 'Native doctors prescribe purnathi for ...diabetes'
The Indian Hemp Drugs Commission, in its report of 1895, states that cannabis was primarily used by the classes of people who engaged in hard physical labor, and who endured harsh environments. The Commission writes that - 'Ganja or charas is chiefly used by (I) "religious" persons, such as
fakirs and wandering mendicants, sadhus and pandahs, the followers of
Trinath, and other sects; (2) the lower classes of both Hindus and
Muhammadans, such as artizans and cultivators, fishermen and boatmen,
palki-bearers and day labourers, sepoys and night watchmen, wrestlers
and athletes, Chamars and Domes, and others of the lower orders; (3)
domestic servants of all kinds, especially those who, as syces, durwans,
or dhobis, have especially trying work to do; (4) aborigines of
different races, such as Sonthals, Gonds, and many more; (5) tradesmen,
Kayasths, and others of the lower middle classes.'
Protection of the pancreas, which secretes the hormones needed to control blood sugar levels, by cannabis is evidenced in the cases where it helps combat pancreatic cancer, one of the most aggressive types of cancer. The pancreatic cancer combating properties of cannabis is an indicator of the role cannabis plays in control of diabetes. Other studies, like the ones which show that the cannabis smoker is generally leaner, with a more healthy body mass index (BMI), has a low waistline circumference, often spends more time on physical tasks and in the gym as compared to the non cannabis smoker, help us see quite clearly how cannabis may help control diabetes. Studies have found that the secretion of natural insulin is better in a
cannabis smoker, and the breakdown of sugars happens more efficiently.
Diabetes is one of the biggest killers in the world today and a high number of individuals are affected by it. It is one more of our modern day lifestyle diseases, with some types of diabetes now affecting even young children who consumer unhealthy amounts of sugar based beverages and spend long hours sitting in front of the television or smartphone, instead of engaging in the traditional physical games of childhood.
Getting yourself diagnosed with diabetes in the modern medical environment means signing yourself up for a lifetime of pharmaceutical drugs that you need to take daily to keep insulin levels under control. If coupled with the medication, you do not observe a strict diet and physical exercise regimens, you may be required to move to the next step of medication, which is injecting yourself with insulin on a daily basis to keep your sugar levels within the healthy range. People have been known to overdose on insulin injections, especially as they grow older and find it difficult to keep track of dosages. Insulin, essentially extracted from animals, mostly bovines, are sold by most major pharma companies and probably form a significant part of their revenues, along with the other diabetes medications. There are world wide shortages of insulin as a medication, and it is often unavailable in the poorer countries or for poorer sections of society. With increased screening, and the constant shifting of goalposts in terms of what constitutes normal sugar level ranges, the number of diabetes patients worldwide, who are recommended to do periodic monitoring tests, and who are prescribed medication that they need to take on a daily basis, runs in the hundreds of millions. Many suffer because they grow dependent on these medications, only to find that the medications are in short supply. By this time, their bodies are unable to produce natural insulin in sufficient quantities, and their health quickly deteriorates to dangerous levels, sometimes leading to death, as they have not developed alternate strategies besides pharmaceutical medication to combat diabetes. There could also very likely be links between pancreatic cancer, as well as kidney failures, and the prolonged use of pharmaceutical based diabetes medication, which warrants further investigation.
Diabetes is one of the biggest killers in the world today and a high number of individuals are affected by it. It is one more of our modern day lifestyle diseases, with some types of diabetes now affecting even young children who consumer unhealthy amounts of sugar based beverages and spend long hours sitting in front of the television or smartphone, instead of engaging in the traditional physical games of childhood.
Getting yourself diagnosed with diabetes in the modern medical environment means signing yourself up for a lifetime of pharmaceutical drugs that you need to take daily to keep insulin levels under control. If coupled with the medication, you do not observe a strict diet and physical exercise regimens, you may be required to move to the next step of medication, which is injecting yourself with insulin on a daily basis to keep your sugar levels within the healthy range. People have been known to overdose on insulin injections, especially as they grow older and find it difficult to keep track of dosages. Insulin, essentially extracted from animals, mostly bovines, are sold by most major pharma companies and probably form a significant part of their revenues, along with the other diabetes medications. There are world wide shortages of insulin as a medication, and it is often unavailable in the poorer countries or for poorer sections of society. With increased screening, and the constant shifting of goalposts in terms of what constitutes normal sugar level ranges, the number of diabetes patients worldwide, who are recommended to do periodic monitoring tests, and who are prescribed medication that they need to take on a daily basis, runs in the hundreds of millions. Many suffer because they grow dependent on these medications, only to find that the medications are in short supply. By this time, their bodies are unable to produce natural insulin in sufficient quantities, and their health quickly deteriorates to dangerous levels, sometimes leading to death, as they have not developed alternate strategies besides pharmaceutical medication to combat diabetes. There could also very likely be links between pancreatic cancer, as well as kidney failures, and the prolonged use of pharmaceutical based diabetes medication, which warrants further investigation.
As if all this is not bad enough, the synthetic pharmaceutical industry, medical industry and governments together decided to create a fake pandemic called Covid-19 in 2019. In the name of this pandemic, governments world wide ordered lockdowns on their people. This prevented vast numbers of the population from leading active lives, resulting in the spiking of diabetes levels. Many decided to visit the hospital, where they were pumped with steroids in the name of Covid treatment. These steroids resulted in further spiking of diabetes levels, besides providing a platform for the resurgence of the deadly fungal disease, mycomucorsis.
One of the key problems that we see today, in terms of factors
contributing to obesity and diabetes, is that not only do we eat unhealthy food,
at unhealthy times, we also tend to overeat, thus creating tremendous
stress on our digestive systems. Obesity is one of the biggest health problems facing humans today. Cannabis was used by many among the poorest classes, including religious mendicants,
to stave off hunger, and also to stay healthy despite reduced
consumption of food. Many witnesses speak of this benefit of cannabis
consumption. In this regard, a detailed account
can be found in the Indian Hemp Commission's report of 1895. Even
though this involved a rhesus macaque, the behavior of the macaque
corroborated the evidence of witnesses in terms of how cannabis helped
one to stay nourished, despite a reduced intake of food. The Hemp
Commission writes in its summary on the effects of cannabis inhalation
as follows: '483. The following interesting account of an experiment
[on a rhesus macaque for eight months] on the effects of the systematic
inhalation of the smoke of ganja conducted by Dr. D.D. Cunningham at the
request of the Commission is extracted from his report (Vol. III
Appendices)...The only permanent appreciable effect resulting from the
treatment manifested itself in the form of a very considerable
diminution in appetite for food, which set in shortly after the
initiation of the experiment, and thereafter remained persistent
throughout its entire course.' Dr. Cunningham reports that - "On
laying the body open, the phenomenon which at once attracted attention,
as unlike any ordinarily present in those of caged monkeys, was the
great amount of fat accumulated in the omentum, the mesentery, and the
visceral and parietal pericardium. This was specially noteworthy in
connection with the markedly diminished ingestion of food which had
characterised the subject of the experiment during the greater part of
its course, and with the coincident considerable reduction in body
weight which had occurred. The body generally appeared to be fairly well
nourished, and a considerable amount of subcutaneous fat was
present....But the only persistent symptom attending the treatment
during life was a considerable diminution in appetite for food, so that,
in so far as the results of a single experiment afford any ground for
inference, it would appear that the most important effect of the
habitual employment of inhalations of the smoke of ganja is to give rise
to diminution in the normal processes of tissue-waste to such a degree
that local accumulations of fat are liable to occur even in spite of the
coincident and similarly originating diminution in the ingestion of
food. The diminution in activity of the normal processes of tissue waste
tends, on the one hand, to give rise to decreased ingestion of food,
and, on the other, to local accumulation of fat in spite of this. But if
the habitual practice of inhalations of the drug really do produce such
effects, it is clear that, in place of being hurtful, it may be
positively beneficial to people who are obliged to undergo exertions
without having the means of procuring a diet fully adapted to make good
the amount of tissue waste normally associated with them."
Cannabis could prove to be a traditional, natural and enjoyable way to prevent and control diabetes, with minimum side effects, at a low cost, and with universal access for individuals worldwide. So when this most simple, affordable, pleasurable and natural way to treat worldwide diabetes is available to humans, why is it not being used? Why, because cannabis is a banned substance worldwide, figuring as a Schedule 1 substance in the UN list of controlled substances under the 1961 Single Convention Treaty on narcotic and psychotropic substances, while sugar based beverages and junk food are widely advertised and promoted. Why, because there may be a number of entities, such as physicians, diagnostic labs, medical insurance companies and pharma companies that stand to lose massive amounts of money if the cannabis plant is legalized and diabetes as a disease is eliminated. So the question is, do we as humans want to really eliminate the disease or are we nurturing and cultivating it for the selfish benefit of a few entities.
Related articles
The following list of articles taken from various media speak about the above subject. Words in italics are the thoughts of yours truly at the time of reading the article.Adults with a history of cannabis use are less likely than non-consumers to develop type 2 diabetes, according to data published in the journal Phytotherapy Research. A team of Iranian investigators performed a meta-analysis of the relevant literature, including 11 surveys and four cohorts consisting of more than 478,000 subjects. They reported, “[T]he odds of developing T2DM [type 2 diabetes] in individuals exposed to cannabis was 0.48 times lower than in those without cannabis exposure.”
Authors speculated that cannabis may possess “protective effects” against the development of diabetes, but they cautioned against drawing any definitive conclusions absent additional studies.
“To our knowledge, our meta-analysis presents the … most up-to-date evidence on the association between cannabis consumption and T2DM,” they concluded. “Given the rising trend of cannabis consumption, and legalization of cannabis consumption there is an increasing need to design prospective longitudinal randomized studies investigating the honest effects of cannabis consumption and providing practical guidelines to manage cannabis usage.”
https://norml.org/news/2023/08/03/analysis-cannabis-consumers-possess-reduced-risk-of-type-2-diabetes/
Researchers at the Tabriz University of Medical Sciences in Iran performed the analysis on “seven studies, containing 11 surveys and 4 cohorts.” According to NORML, which aggregated the analysis, the four cohorts consisted of more than 478,000 subjects.
The meta-analysis revealed that “the odds of developing [type 2 diabetes mellitus] in individuals exposed to cannabis was 0.48 times (95% CI: 0.39 to 0.59) lower than in those without cannabis exposure,” according to the researchers.
The researchers noted that “protective effect of cannabis consumption on the odds of diabetes mellitus type 2 development has been suggested,” although they added that “given the considerable interstudy heterogeneity, the upward trend of cannabis consumption and cannabis legalization is recommended to conduct studies with higher levels of evidence.”
https://hightimes.com/study/study-suggests-cannabis-users-have-lower-risk-of-type-2-diabetes/
Authors speculated that cannabis may possess “protective effects” against the development of diabetes, but they cautioned against drawing any definitive conclusions absent additional studies.
“To our knowledge, our meta-analysis presents the … most up-to-date evidence on the association between cannabis consumption and T2DM,” they concluded. “Given the rising trend of cannabis consumption, and legalization of cannabis consumption there is an increasing need to design prospective longitudinal randomized studies investigating the honest effects of cannabis consumption and providing practical guidelines to manage cannabis usage.”
https://norml.org/news/2023/08/03/analysis-cannabis-consumers-possess-reduced-risk-of-type-2-diabetes/
Researchers at the Tabriz University of Medical Sciences in Iran performed the analysis on “seven studies, containing 11 surveys and 4 cohorts.” According to NORML, which aggregated the analysis, the four cohorts consisted of more than 478,000 subjects.
The meta-analysis revealed that “the odds of developing [type 2 diabetes mellitus] in individuals exposed to cannabis was 0.48 times (95% CI: 0.39 to 0.59) lower than in those without cannabis exposure,” according to the researchers.
The researchers noted that “protective effect of cannabis consumption on the odds of diabetes mellitus type 2 development has been suggested,” although they added that “given the considerable interstudy heterogeneity, the upward trend of cannabis consumption and cannabis legalization is recommended to conduct studies with higher levels of evidence.”
https://hightimes.com/study/study-suggests-cannabis-users-have-lower-risk-of-type-2-diabetes/
'Researchers affiliated with the University of Chicago and with Tarleton University in Texas assessed the daily use of CBD in a cohort of over 1,000 adults. Most of the study’s participants reported having consumed full-spectrum CBD tinctures for at least one year.
Investigators concluded: “In this large-sample study, self-dosing [with] CBD was not associated with an increased prevalence of elevation of LT [liver tests] or low levels of TT [total testosterone] in men. Furthermore, CBD administration decreased DD [daytime drowsiness] and was associated with a lower prevalence of low testosterone levels in older men as compared to age-adjusted population norms. … [I]n those over 45 years of age, the prevalence of type 2 diabetes was significantly lower than that of the general population.”
Several population-based studies have reported that cannabis consumers typically possess lower BMI and other favorable indices related to diabetic control. Observational studies have also shown that the past use of cannabis is significantly associated with lower odds of diabetes in adults.
Data published in 2021 similarly determined that the repeated use of oral CBD products is not associated with liver abnormalities, such as the elevated production of the enzyme alanine transaminase.'
https://norml.org/news/2023/04/06/study-daily-use-of-cbd-tinctures-associated-with-decreased-daytime-drowsiness-no-increased-risk-of-liver-disease/
Investigators concluded: “In this large-sample study, self-dosing [with] CBD was not associated with an increased prevalence of elevation of LT [liver tests] or low levels of TT [total testosterone] in men. Furthermore, CBD administration decreased DD [daytime drowsiness] and was associated with a lower prevalence of low testosterone levels in older men as compared to age-adjusted population norms. … [I]n those over 45 years of age, the prevalence of type 2 diabetes was significantly lower than that of the general population.”
Several population-based studies have reported that cannabis consumers typically possess lower BMI and other favorable indices related to diabetic control. Observational studies have also shown that the past use of cannabis is significantly associated with lower odds of diabetes in adults.
Data published in 2021 similarly determined that the repeated use of oral CBD products is not associated with liver abnormalities, such as the elevated production of the enzyme alanine transaminase.'
https://norml.org/news/2023/04/06/study-daily-use-of-cbd-tinctures-associated-with-decreased-daytime-drowsiness-no-increased-risk-of-liver-disease/
'Compared to placebo, cannabinoid therapy was associated with a “statistically significant decline in total cholesterol, triglycerides, LDL-C, FBS [fasting blood glucose levels], Hb [hemoglobin] A1C, and insulin secretion … at the end of the 8-week treatment period. … [T]here were no statistically significant differences in reported adverse effects between the two groups.”
Researchers concluded: “In the present study, we demonstrated that sublingual administration of [a CBD/THC] spray, … twice daily through an eight-week treatment period could effectively improve the patient’s lipid profile and glucose tolerance. … Based on these observations, the combination of CBD/delta9-THC regimen could be a new therapeutic regimen for controlling the lipid profile and glycemic state of DM [type 2 diabetic] patients.”'
https://norml.org/news/2023/03/30/clinical-trial-cbd-thc-combination-controls-blood-sugar-lowers-cholesterol-in-type-2-diabetics/
Researchers concluded: “In the present study, we demonstrated that sublingual administration of [a CBD/THC] spray, … twice daily through an eight-week treatment period could effectively improve the patient’s lipid profile and glucose tolerance. … Based on these observations, the combination of CBD/delta9-THC regimen could be a new therapeutic regimen for controlling the lipid profile and glycemic state of DM [type 2 diabetic] patients.”'
https://norml.org/news/2023/03/30/clinical-trial-cbd-thc-combination-controls-blood-sugar-lowers-cholesterol-in-type-2-diabetics/
'Authors concluded: “This 28-day trial revealed statistically and clinically significant improvement in pain and a clinically significant improvement in sleep quality and in anxiety reduction for those in the CBD treatment group. Additionally, subjects taking CBD affirmed these results by having a statistically significant greater response to treatment as compared with subjects taking placebo. The benefit of this study demonstrates that the sublingual 20 mg CBD tablet should be considered as a safe and effective treatment for pDPN.”
Numerous placebo-controlled clinical trials similarly document the ability of whole-plant cannabis to mitigate neuropathic pain in a wide range of patient populations, including in subjects with HIV and diabetes.'
https://norml.org/news/2021/08/05/clinical-trial-sublingual-administration-of-cbd-is-effective-in-patients-with-diabetic-neuropathy
Numerous placebo-controlled clinical trials similarly document the ability of whole-plant cannabis to mitigate neuropathic pain in a wide range of patient populations, including in subjects with HIV and diabetes.'
https://norml.org/news/2021/08/05/clinical-trial-sublingual-administration-of-cbd-is-effective-in-patients-with-diabetic-neuropathy
'Doctors believe mucormycosis, which has an overall mortality rate of 50%, may be being triggered by the use of steroids, a life-saving treatment for severe and critically ill Covid-19 patients.
Steroids reduce inflammation in the lungs for Covid-19 and appear to help stop some of the damage that can happen when the body's immune system goes into overdrive to fight off coronavirus. But they also reduce immunity and push up blood sugar levels in both diabetics and non-diabetic Covid-19 patients.
It's thought that this drop in immunity could be triggering these cases of mucormycosis.'
https://www.bbc.com/news/world-asia-india-57027829
Steroids reduce inflammation in the lungs for Covid-19 and appear to help stop some of the damage that can happen when the body's immune system goes into overdrive to fight off coronavirus. But they also reduce immunity and push up blood sugar levels in both diabetics and non-diabetic Covid-19 patients.
It's thought that this drop in immunity could be triggering these cases of mucormycosis.'
https://www.bbc.com/news/world-asia-india-57027829
Symptoms of pulmonary (lung) mucormycosis include: Fever, Cough, Chest pain, Shortness of breath
These fungi aren’t harmful to most people. However, for people who have weakened immune systems, breathing in mucormycete spores can cause an infection in the lungs or sinuses which can spread to other parts of the body.
Risk groups for mucormycosis include persons with uncontrolled diabetes; malignancy; hematopoietic stem cell transplant or solid organ transplant; persistent neutropenia; prolonged corticosteroid therapy; skin trauma, burns, or surgical wounds; iron overload; intravenous drug use; malnourishment; and premature infants.
Mucormycosis is frequently a life-threatening infection. A review of published mucormycosis cases found an overall all-cause mortality rate of 54%. The mortality rate varied depending on underlying patient condition, type of fungus, and body site affected (for example, the mortality rate was 46% among people with sinus infections, 76% for pulmonary infections, and 96% for disseminated mucormycosis).
https://www.cdc.gov/fungal/diseases/mucormycosis/statistics.html
These fungi aren’t harmful to most people. However, for people who have weakened immune systems, breathing in mucormycete spores can cause an infection in the lungs or sinuses which can spread to other parts of the body.
Risk groups for mucormycosis include persons with uncontrolled diabetes; malignancy; hematopoietic stem cell transplant or solid organ transplant; persistent neutropenia; prolonged corticosteroid therapy; skin trauma, burns, or surgical wounds; iron overload; intravenous drug use; malnourishment; and premature infants.
Mucormycosis is frequently a life-threatening infection. A review of published mucormycosis cases found an overall all-cause mortality rate of 54%. The mortality rate varied depending on underlying patient condition, type of fungus, and body site affected (for example, the mortality rate was 46% among people with sinus infections, 76% for pulmonary infections, and 96% for disseminated mucormycosis).
https://www.cdc.gov/fungal/diseases/mucormycosis/statistics.html
'Cannabidiol (CBD), a phytocannabinoid compound, presents antidepressant and anxiolytic-like effects in the type-1 diabetes mellitus(DM1) animal model. Although the underlying mechanism remains unknown, the type-1A serotonin receptor (5-HT1A) and cannabinoids type-1 (CB1) and type-2 (CB2) receptors seem to play a central role in mediating the beneficial effects on emotional responses. We aimed to study the involvement of these receptors on an antidepressant and anxiolytic-like effects of CBD and on some parameters of the diabetic condition itself. After 2 weeks of the DM1 induction in male Wistar rats by streptozotocin (60 mg/kg; i.p.), animals were treated continuously for 2-weeks with the 5-HT1A receptor antagonist WAY100635 (0.1 mg/kg, i.p.), CB1 antagonist AM251 (1 mg/kg i.p.) or CB2 antagonist AM630 (1 mg/kg i.p.) before the injection of CBD (30 mg/kg, i.p.) or vehicle (VEH, i.p.) and then, they were submitted to the elevated plus-maze and forced swimming tests. Our findings show the continuous treatment with CBD improved all parameters evaluated in these diabetic animals. The previous treatment with the antagonists - 5-HT1A, CB1, or CB2 - blocked the CBD-induced antidepressant-like effect whereas only the blockade of 5-HT1A or CB1 receptors was able to inhibit the CBD-induced anxiolytic-like effect. Regarding glycemic control, only the blockade of CB2 was able to inhibit the beneficial effect of CBD in reducing the glycemia of diabetic animals. These findings indicated a therapeutic potential for CBD in the treatment of depression/anxiety associated with diabetes pointing out a complex intrinsic mechanism in which 5-HT1A, CB1, and/or CB2 receptors are differently recruited.'
https://link.springer.com/article/10.1007/s11011-020-00667-3
https://link.springer.com/article/10.1007/s11011-020-00667-3
'Results: As a result, body weight gain, epididymal, and perirenal adipose tissue decreased in the CSSF (Cannabis sativa seed Flour) group in both doses (100 mg/kg and 200 mg/kg) compared to the HCD. CSSF lowered serum glucose level elevated by HCD. For lipid profiles, total cholesterol (TC), HDL-cholesterol, LDL-cholesterol, and triglycerides (TG) significantly decreased in the CSSF group. The histopathological results of this study showed a regenerative effect of CSSF on the kidney and liver tissues.
Conclusion: It is concluded from the present study that CSSF can be used as a natural anti-obesity agent.'
https://www.researchgate.net/profile/Bouarfa_Mouna2/publication/345396297_ANTI-OBESITY_EFFECT_OF_CANNABIS_SATIVA_SEED_FLOUR_FROM_KHLALFA_OF_TAOUNATE_REGION_NORTHERN_OF_MOROCCO_IN_HIGH_CALORIC_DIET-INDUCED_OBESE_MICE/links/5fa6f00092851cc2869d76ec/ANTI-OBESITY-EFFECT-OF-CANNABIS-SATIVA-SEED-FLOUR-FROM-KHLALFA-OF-TAOUNATE-REGION-NORTHERN-OF-MOROCCO-IN-HIGH-CALORIC-DIET-INDUCED-OBESE-MICE.pdf
Conclusion: It is concluded from the present study that CSSF can be used as a natural anti-obesity agent.'
https://www.researchgate.net/profile/Bouarfa_Mouna2/publication/345396297_ANTI-OBESITY_EFFECT_OF_CANNABIS_SATIVA_SEED_FLOUR_FROM_KHLALFA_OF_TAOUNATE_REGION_NORTHERN_OF_MOROCCO_IN_HIGH_CALORIC_DIET-INDUCED_OBESE_MICE/links/5fa6f00092851cc2869d76ec/ANTI-OBESITY-EFFECT-OF-CANNABIS-SATIVA-SEED-FLOUR-FROM-KHLALFA-OF-TAOUNATE-REGION-NORTHERN-OF-MOROCCO-IN-HIGH-CALORIC-DIET-INDUCED-OBESE-MICE.pdf
'Hepatitis C-infected subjects who use cannabis possess a lower risk of diabetes, according to data published in the Journal of Viral Hepatitis.
A team of French investigators assessed the relationship between cannabis consumption and diabetes prevalence in a nationally representative sample of over 10,000 subjects with hepatitis C. Because chronic hepatitis C virus (HCV) infection is a risk factor of insulin resistance, HCV-infected patients are at a higher risk of developing diabetes than those in the general population.'
https://norml.org/news/2020/08/27/study-cannabis-use-associated-with-reduced-rates-of-diabetes-in-patients-with-hepatitis-c
A team of French investigators assessed the relationship between cannabis consumption and diabetes prevalence in a nationally representative sample of over 10,000 subjects with hepatitis C. Because chronic hepatitis C virus (HCV) infection is a risk factor of insulin resistance, HCV-infected patients are at a higher risk of developing diabetes than those in the general population.'
https://norml.org/news/2020/08/27/study-cannabis-use-associated-with-reduced-rates-of-diabetes-in-patients-with-hepatitis-c
'Chronic hepatitis C virus (HCV) infection is a risk factor of insulin resistance, and HCV-infected patients are at a high risk of developing diabetes. In the general population, research has shown the potential benefit of cannabis use for the prevention of diabetes and related metabolic disorders. We aimed to test whether cannabis use is associated with a lower risk of diabetes in chronic HCV-infected patients...In this large cross-sectional study of chronic HCV-infected patients, cannabis use was associated with a lower risk of diabetes independently of clinical and socio-behavioral factors. Further studies are needed to elucidate a potential causal link and shed light on cannabis compounds and mechanisms involved in this relationship.'
https://pubmed.ncbi.nlm.nih.gov/32810343/
https://pubmed.ncbi.nlm.nih.gov/32810343/
'Overweight, insulin resistance and obesity emerged as leading health
concerns all over the world. The above mentioned disturbances are
characterized by excessive or abnormal fat accumulation, and are major
risk factors for a number of chronic diseases, such as cardiovascular
diseases, diabetes, and cancer. Currently, the non-psychotropic
component of Cannabis sativa—CBD is in the center of interest, due to
its well-established anti-inflammatory, anti-oxidant, anti-convulsant,
anti-psychotic and potential anti-obesity properties. Many studies
indicated that CBD affects both lipid and glucose metabolism through the
action on various receptors as well as several metabolites. From the
existing data, we can conclude that CBD has the promising potential as a
therapeutic agent and might be effective in alleviating the symptoms of
insulin resistance, type 2 diabetes and metabolic syndrome'
https://www.frontiersin.org/articles/10.3389/fendo.2020.00114/full
https://www.frontiersin.org/articles/10.3389/fendo.2020.00114/full
'Against previous background of plausible harms from marijuana, metabolic risk estimates from current data suggest a protective effect. Recent studies report that marijuana use is associated with decreased risk of metabolic abnormalities such as obesity, diabetes, and metabolic syndrome.'
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0186702
'Large waist circumference is linked to diabetes risk. In the current study there were also significant associations between marijuana use and smaller waist circumferences.'
https://www.elsevier.com/about/press-releases/research-and-journals/novel-study-reports-marijuana-users-have-better-blood-sugar-control
'Metabolic syndrome, a significant risk factor for type 2 diabetes and cardiovascular disease is defined as the presence of a cluster of >=3 of the following risk factors: elevated waist circumference, systolic or diastolic blood pressure (or both), triglycerides, fasting glucose, and low high-density lipoprotein (HDL) cholesterol.
Current and past marijuana use were both associated with lower prevalence of metabolic syndrome and most of its components.'
https://www.amjmed.com/article/S0002-9343(15)01024-4/fulltext
'Roughly 20% of the population of Vanuatu has diabetes, according to a 2012 survey cited last November by the country’s minister of health, Jerome Ludvaune. “We the citizens of this country have changed our lifestyle very quickly,” he said. “Therefore we are now in a situation where we will face a hard time in controlling this sickness.’’
World Health Organization (WHO) data from 2016 indicated that 13.1% of the Vanuatu population has diabetes, and the population largely lacks access to traditional treatments. Insulin, WHO says, is “not generally available.”'
https://www.leafly.com/news/politics/pacific-island-nation-of-vanuatu-legalizes-medical-cannabis
'Almost 500 participants said they endorse using marijuana one hour before, or up to four hours after, exercising. And based on data from the questionnaire, those who did use cannabis in that timeframe worked out longer than consumers who didn’t pair the activities. Specifically, those who engaged in co-use worked out an average of 43 minutes longer for aerobic exercise and 30 minutes longer for anaerobic exercise.
What’s behind the trend?'
https://www.marijuanamoment.net/study-finds-marijuana-motivates-people-to-exercise-smashing-lazy-stoner-stereotype/
'The stereotypical image of a cannabis smoker is someone who sprawls on the sofa for hours surrounded by a haze of smoke and half-eaten snacks. The scene is played up for laughs in films, but social psychologist Angela Bryan thought it could be cause for concern. After all, cannabis is known to increase appetite and aid relaxation, which might put people at risk of health conditions such as obesity, says Bryan, who is at the University of Colorado Boulder.
But digging into health trends revealed the opposite. Nationwide US studies report that, compared to non-users, cannabis users actually have a lower prevalence of obesity.'
https://www.nature.com/articles/d41586-019-02529-0
'“People in their 80s and 90s, even retired Air Force colonels, are finding such relief” with cannabis, said Ms. Horne. “Almost everybody I know is using it in one form or another” — including her husband Hal, 68, a retired insurance broker, who says it helps him sleep.
In fact, so many Laguna Woods seniors use medical cannabis — for ailments ranging from arthritis and diabetes nerve pain to back injuries and insomnia — that the local dispensary, Bud and Bloom, charters a free bus to bring residents to its Santa Ana location to stock up on supplies. Along with a catered lunch, the bus riders get a seniors discount.'
https://www.nytimes.com/2018/12/07/health/seniors-marijuana-cannabis-pain.html
'Greater cannabis exposure was associated with relatively lower BMI (ß=-0.31, p<.001), smaller WHR (ß=-0.23, p=.002), better HDL (ß=0.14, p=.036) and LDL cholesterol (ß=-0.15, p=.026), lower triglycerides (ß=-0.17, p=.009), lower fasting glucose (ß=-0.15, p<.001) and HOMA-IR (ß=-0.21, p=.003), lower systolic (ß=-0.22, p<.001) and diastolic blood pressure (ß=-0.15, p=.028), and fewer metabolic syndrome criteria (ß=-0.27, p<.001). With exception of BMI, cannabis users' mean levels on cardiometabolic risk factors were generally below clinical cutoffs for high risk. Most associations between cannabis use and cardiometabolic risk factors remained after adjusting for tobacco use, childhood SES, and childhood health. However, after adjusting for adult BMI, these associations were no longer apparent, and mediation tests suggested that cannabis users' relatively lower BMI might explain their lower levels of risk on other cardiometabolic risk factors.'
https://www.ncbi.nlm.nih.gov/pubmed/30589665?dopt=Abstract
No comments:
Post a Comment